作者:Ying-zi Xu、Andrei W. Konradi、Frederique Bard、Michael Dappen、Lilibeth Dofiles、Mark Dreyer、Ian Gallager、Caroline Garrido、Mike Krimm、Zhenmei Liao、Elizabeth Messersmith、Linda Mutter、Michael A. Pleiss、Bhushan Samant、Christopher M. Semko、Jennifer Smith、Frank Stappenbeck、Brian Stupi、Chris Vandervert、Brent Welch、Brian Wipke、Ted Yednock
DOI:10.1016/j.bmcl.2013.03.010
日期:2013.5
A series of (S)-2-(2-(diethylamino)-5-(N-alkyl-N-sulfonamido)pyrimidin-4-ylamino)-3-(4-(carbamoyloxy)phenyl)propanoic acid is discovered as orally available VLA-4 antagonists. Representative compounds 11b and 11p showed efficacy in multiple in vivo animal models. The in vitro selectivity of 11p is also described. (C) 2013 Elsevier Ltd. All rights reserved.